New Data Presented at ESMO 2017 Shows That Abiraterone Acetate Plus Prednisone Provides Benefits in Patient Reported Outcomes in Both Metastatic Hormone-Sensitive and Castration-Resistant Prostate Cancer
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
More News: Abiraterone Acetate | Cancer | Cancer & Oncology | Hormones | Pharmaceuticals | Prednisone | Prostate Cancer